<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892498</url>
  </required_header>
  <id_info>
    <org_study_id>JD-LK-2021-035-01</org_study_id>
    <nct_id>NCT04892498</nct_id>
  </id_info>
  <brief_title>Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)</brief_title>
  <official_title>A Prospective Multicenter Clinical Study of Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective multicenter clinical study to determine the efficacy and safety of&#xD;
      hypofractionated radiotherapy combined with PD-1 inhibitor sequential GM-CSF and IL-2 for&#xD;
      advanced multiple metastatic solid tumors&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 30, 2021</start_date>
  <completion_date type="Anticipated">August 2024</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival，PFS</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from cycle 1, day 1 of treatment to disease progression or death due to any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate，ORR</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The proportion of patients with at least one tumor scan of complete response (CR) or partial response (PR) using RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate，DCR</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>The proportion of patients with at least one tumor scan of complete response (CR) or partial response (PR) or stable disease (SD) using RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival，OS</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>Time from cycle 1, day 1 of treatment until death due to any cause</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">66</enrollment>
  <condition>Advanced Refractory Solid Tumors</condition>
  <arm_group>
    <arm_group_label>RT+PD-1+GM-CSF+IL-2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated radiotherapy</intervention_name>
    <description>10-24Gy/5-8Gy/2-3f</description>
    <arm_group_label>RT+PD-1+GM-CSF+IL-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 inhibitor</intervention_name>
    <description>q3w, until PD</description>
    <arm_group_label>RT+PD-1+GM-CSF+IL-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GM-CSF</intervention_name>
    <description>200μg, D1-D7, ≥8 cycles</description>
    <arm_group_label>RT+PD-1+GM-CSF+IL-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IL-2</intervention_name>
    <description>at a dose of 2 million IU, D8-D14, ≥8 cycles</description>
    <arm_group_label>RT+PD-1+GM-CSF+IL-2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years.&#xD;
&#xD;
          2. The enrolled patients meet the recurrence or metastasis of advanced solid malignant&#xD;
             tumors, have a clear pathological diagnosis report or medical history, the guidelines&#xD;
             do not clearly recommend standard treatment plans or cannot tolerate standard&#xD;
             treatment plans, and have clear measurable metastatic lesions (&gt;1cm);&#xD;
&#xD;
          3. No congestive heart failure, unstable angina, or unstable arrhythmia occurred in the&#xD;
             past 6 months.&#xD;
&#xD;
          4. The patient's activity status score is 0-3 points based on the Eastern Cooperative&#xD;
             Oncology Group (ECOG) scoring method, and the life expectancy assessment is ≥3 months.&#xD;
&#xD;
          5. No serious hematopoietic function, abnormal heart, lung, liver, kidney function and&#xD;
             immune deficiency in the past.&#xD;
&#xD;
          6. One week before admission, the absolute value of T lymphocytes was ≥0.5 times the&#xD;
             lower limit of normal, and neutrophils ≥1.0×109/L; AST and ALT were ≤3.0 times the&#xD;
             upper limit of normal (for liver cancer/liver metastasis ≤5.0 times) Upper limit of&#xD;
             normal); creatinine ≤3.0 times the upper limit of normal.&#xD;
&#xD;
          7. The patient have the ability to understand and voluntarily sign an informed consent&#xD;
             form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or breastfeeding women.&#xD;
&#xD;
          2. Those with a history of other malignant diseases in the last 5 years, except for cured&#xD;
             skin cancer and cervical carcinoma in situ.&#xD;
&#xD;
          3. If there is a history of uncontrolled epilepsy, central nervous system disease or&#xD;
             mental disorder, the investigator's judgment of its clinical severity may hinder the&#xD;
             signing of informed consent or affect the patient's compliance with medication.&#xD;
&#xD;
          4. Clinically serious (ie active) heart disease, such as symptomatic coronary heart&#xD;
             disease, New York Heart Association (NYHA) grade II or more severe congestive heart&#xD;
             failure, or severe arrhythmia requiring drug intervention, or recent A history of&#xD;
             myocardial infarction within 12 months.&#xD;
&#xD;
          5. Those who need immunosuppressive therapy for organ transplantation.&#xD;
&#xD;
          6. A known major active infection, or the researcher's judgment has major blood, kidney,&#xD;
             metabolism, gastrointestinal, endocrine function or metabolic disorders, or other&#xD;
             serious uncontrolled accompanying diseases.&#xD;
&#xD;
          7. Those who are allergic to any research drug ingredients.&#xD;
&#xD;
          8. A history of immunodeficiency, including HIV positive or other acquired or congenital&#xD;
             immunodeficiency diseases, or a history of organ transplantation, or those with other&#xD;
             immune-related diseases that require long-term oral hormone therapy.&#xD;
&#xD;
          9. In the period of acute and chronic tuberculosis infection (T-spot test is positive,&#xD;
             patients with suspected tuberculosis foci on chest X-ray).&#xD;
&#xD;
         10. Other situations that the researcher thinks are not suitable for inclusion in the&#xD;
             group.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Liyuan Zhang, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Liyuan Zhang, Dr</last_name>
    <phone>0086-0512-67784827</phone>
    <email>zhangliyuan126@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hao Wang, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pei Yang, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pin Liu, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xiangya Hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Haijun Wu, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chongqing University Cancer Hospital</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wei Zhou, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Sixth Affiliated Hospital ，Sun Yat-seen University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiangbo Wan, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of The University of Chinese Academy of Sciences</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Feng, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of USTC</name>
      <address>
        <city>Hefei</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dong Qian, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shandong Provincial Tumor Hospital</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dali Han, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Nanchang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hua Wang, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangsu Cancer Hospital</name>
      <address>
        <city>Nanjing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Li Yin, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guichao Li, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liyuan Zhang, Dr</last_name>
      <phone>0086-0512-67784827</phone>
      <email>zhangliyuan126@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renmin Hospital of Wuhan University</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xiangpan Li, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Jiangyin People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiang Wang, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affilated Hospital of Xuzhou Medical University</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiangshe Wang, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>May 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hypofractionated radiotherapy</keyword>
  <keyword>PD-1 inhibitor</keyword>
  <keyword>GM-CSF</keyword>
  <keyword>IL-2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

